Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Shares of Danish drugmaker Novo Nordisk (NYSE: NVO) have been in a full-blown tailspin over the past 12 months. The stock has lost more than half of its value as the company has been delivering some underwhelming results recently, and its guidance isn't looking too promising, either. It's been a bit of a perfect storm that has resulted in Novo Nordisk stock now tumbling to levels it hasn't been at since early 2021. That's even before its weight loss drug, Wegovy, obtained approval from regulators, which was ...